L-DOPAL-DOPA
MedChemExpress (MCE)
HY-N0304
59-92-7
Levodopa
3,4-Dihydroxyphenylalanine
99.98%
4°C, stored under nitrogen *The compound is unstable in solutions, freshly prepared is recommended.
Room temperature in continental US
may vary elsewhere.
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.
L-DOPA can be used to create movement disorder models. In adult common marmosets, after oral administration of L-DOPA (20/5 mg/kg), the Tmax in plasma is 30 minutes, and the Tmax in striatal extracellular fluid (ECF) is 60-90 minutes. The mean Cmax of L-DOPA in plasma is 20.3 μM, while the mean Cmax in striatal ECF is 442.9 nM, representing about 2.2% of the plasma level[6]. .f12{ font-size: 12px
} .fwb{ font-weight: bold
} .lh22{ line-height: 22px
} .lh23 { line-height: 23px
} .pl13{ padding-left: 13px
} .part { margin-top: 18px
} .mold-first-tit { width: 100%
height: 44px
line-height: 44px
background: #F9F7FB
border-bottom: 1px solid #EBE4F6
padding-left: 16px
box-sizing: border-box
margin-bottom: 17px
} .mold-second-tit:before { content:"
width: 6px
height: 6px
display: inline-block
border-radius: 50%
background: rgba(255,102,0,0.4)
margin-right: 12px
position: relative
top: -3px
} .lft-border { border-left: 1px dotted #EBE4F6
padding-right: 12px
margin-left: 3px
box-sizing: border-box
padding-bottom: 12px
} /* .part .dec:last-child { border-bottom: 0
} */ .dec { margin: 10px 15px 0
padding-bottom: 10px
border-bottom: 1px dashed #EBE4F6
} .btm-border { border-left: 1px dashed #EBE4F6
} .text-bg { margin-top: 10px
background: #FFFBF1
padding: 14px
border-bottom: 0
position: relative
} .text-note-bg { margin-top: 10px
background: #FFFDF7
padding: 12px
border-bottom: 0
position: relative
} .text-note { width: 51px
height: 20px
line-height: 20px
background: #FFE2AA
text-align: center
border-radius: 0 0 8px 0
position: absolute
top: 0
left: 0
} .text-note-dec { margin-top: 15px
} Induction of dyskinesia model[5] Background L-DOPA-induced dyskinesia results from a pulsatile stimulation of brain dopamine (DA) receptors, triggering a complex cascade of molecular and synaptic alterations within the basal ganglia[5]. Specific Mmodeling Methods Mice: C57Bl/6 mice • male • 8 weeks (period: 21 days)Administration: 20 mg/kg • ip • once daily for 21 days Note (1) sustained unilateral 6-OHDA injections in the striatum before starting treatment.(2) Injection volume is 10mL/kg body weight. Modeling Indicators Behavioral changes: Shows developed abnormal involuntary movements (AIMs) affecting the head, trunk and forelimb on the side contralateral to the lesion. Correlated Product(s): Oxidopamine hydrochloride (HY-B1081) Opposite Product(s): Oxidopamine hydrobromide (HY-B1081A)
Human Endogenous Metabolite
| | | |
| | | | | |
[1]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec
38(12):2405-10. [Content Brief]
[2]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008
14(4):273-80. Epub 2007 Nov 7. [Content Brief]
[3]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3
10:237. [Content Brief]
[4]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1
54(2):330-5. [Content Brief]
[5]. M Lundblad, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol. 2005 Jul
194(1):66-75. [Content Brief]
[6]. Jie Zhang, et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res. 2003 Dec 12
993(1-2):54-8. [Content Brief]
